Three COVID-19 trials are on hold as cases surge, with an average of over 60,000 new cases per day in the U.S. over the last week. The pauses have exacerbated concerns that vaccines in particular are being rushed through the safety and efficacy trial process.
These kinds of pauses are fairly ordinary in the system for vaccination approval. On Thursday, a member of that National Institute of Health addressed the holds on clinical trials for Johnson & Johnson and AstraZeneca at a meeting of the Vaccines and Related Biological Products Advisory Committee, which is providing oversight to the many COVID-19 vaccine efforts.
“Adverse events are expected in both the vaccine and placebo group,” said Hilary Marston, a medical officer at the National Institutes of Health and a policy adviser for Pandemic Preparedness, at the meeting. “We are finding these events because we are specifically looking for them, and we are looking for them according to tried and true processes.”
She…
Read More…
Source : fastcompany.com
Source link
